The National Healthcare Security Administration (NHSA) announced that it has been decided to delay the National Reimbursement Drug List (NRDL) on-site negotiations process for this year, citing COVID-19 disruptions and ongoing workload related to preparing for the negotiations. When a new time slot is decided, the negotiating groups will be informed one week prior to taking place.
Reimbursement Agreement Extension
For any drug on the NRDL with a negotiated agreement that is set to expire on December 31, 2022, their reimbursement agreements will remain effective until the negotiations for this year’s NRDL update are rescheduled and the new list implemented.-Fineline Info & Tech
